Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Docetaxel + Pembrolizumab
Indication/Tumor Type lung non-small cell carcinoma
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lung non-small cell carcinoma not applicable Docetaxel + Pembrolizumab Phase II Actionable In a Phase II trial (PROLUNG), combination of Keytruda (pembrolizumab) and Taxotere (docetaxel) significantly improved objective response rate (42.5% vs 15.8%, OR=3.94, p=0.01) and progression-free survival (PFS) (9.5 vs 3.9 mo, HR=0.24, p<0.001) compared to Taxotere (docetaxel) alone in patients with advanced non-small cell lung cancer, PFS was improved in patients with (6.8 vs 3.5 mo, p=0.04) and without (9.5 vs 4.1 mo, p<0.01) EGFR alterations (PMID: 32271354; NCT02574598). 32271354
PubMed Id Reference Title Details
(32271354) Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. Full reference...